COMP <GO>
CLX vs PG // FORWARD P/E MULTIPLE
Clorox Company (The) (NYSE) VS. Procter & Gamble Company (The) (NYSE) • 15-METRIC TALLY: CLX 6
— PG 8
▲ FORWARD P/E MULTIPLE LEADER: CLX
LAST: $88.00 (-0.76%) • MKT CAP: $10.72B
forward-pe
12.1x
LAST: $161.57 (+0.61%) • MKT CAP: $372.21B
forward-pe
21.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLX VS. PG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLX | PG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.20% | 51.20% | -6.00 | PG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 37.20% | 25.40% | +11.80 | CLX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.9x | 16.2x | -5.30 | CLX | /valuation <GO> |
| Free Cash Flow Yield | 7.10% | 3.77% | +3.33 | CLX | /fcf-yield <GO> |
| Operating Margin | 14.20% | 24.30% | -10.10 | PG | /operating-margins <GO> |
| Net Profit Margin | 11.60% | 19.00% | -7.40 | PG | /net-margins <GO> |
| Revenue Growth (YoY) | 0.20% | 0.30% | -0.10 | PG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 5.61% | 2.65% | +2.96 | CLX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.93 | 5.59 | -2.66 | PG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.50% | +0.20 | PG | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.8 | 62.7 | -8.84 | PG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 0.87 | +0.06 | CLX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 12.1x | 21.7x | -9.60 | CLX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.72B | $372.21B | -$361.49B | PG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLX REV | PG REV | CLX GROSS % | PG GROSS % | CLX FCF | PG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.10B | $84.28B | 45.2% | 51.2% | $761.0M | $14.04B |
| FY 2024 | $7.09B | $84.04B | 43.0% | 51.4% | $483.0M | $16.52B |
| FY 2023 | $7.39B | $82.01B | 44.0% | 44.0% | $825.5M | $13.16B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLX // BETA 0.93
PG // BETA 0.87